Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Jul 3, 2026, 23:08For Jatinder Minhas, The Strength of Simulation Training Is Learning Together Across Disciplines – ESO
-
Jul 3, 2026, 22:47Khaled Musallam: Caring for Women with Thalassemia From Puberty to Pregnancy and Beyond
-
Jul 3, 2026, 21:25Matteo Foschi: Happy to Join the Italian Stroke Association Summer School
-
Jul 3, 2026, 20:39Maha Othman: Excited to Present on PPH for The Lancet Haematology Commission on Global Female Health
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics